Thymus Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: THY025 MIFTS: 57	Thymus Cancer Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Thymus Cancer

MalaCards integrated aliases for Thymus Cancer:

Name: Thymus Cancer ¹¹ ⁴¹ ¹⁴

Malignant Neoplasm of Thymus ⁷¹ ³¹

Thymus Neoplasms ⁴³ ⁷¹

Thymus Neoplasm ⁷⁵ ¹⁶

Thymic Tumor ¹¹ ⁵⁸

Primary Malignant Neoplasm of Thymus ³³

Malignant Tumour of Thymus ³³

Thymic Glandular Cancer ³³

Thymus Gland Cancer ³³

Neoplasm of Thymus ¹¹

Thymoma, Familial ⁷¹

Thymic Carcinoma ⁷¹

Thymic Neoplasms ⁵³

Cancer of Thymus ³³

Thymic Neoplasm ¹¹

Thymoma, Type C ⁷¹

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases Genetic diseases
Anatomical: Immune diseases Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms of respiratory and intrathoracic organs

Malignant neoplasm of thymus

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of middle ear, respiratory or intrathoracic organs

Malignant neoplasms of thymus

Carcinoma of thymus

Malignant neoplasms of thymus, unspecified

Other specified malignant neoplasms of thymus

External Ids:

Disease Ontology ¹¹ DOID:3277

ICD9CM ³⁴ 164.0

MeSH ⁴³ D013953

NCIt ⁴⁹ C4962

SNOMED-CT ⁶⁸ 94096009

ICD10 ³¹ C37

UMLS via Orphanet ⁷² C3714644

Orphanet ⁵⁸ ORPHA100100

EFO ¹⁶ EFO_0002626

ICD11 ³³ 1351671383 1718833206 1718833206/other more

UMLS ⁷¹ C0205969 C0751552 C1322286 more

Sources

Summaries for Thymus Cancer

MedlinePlus: ⁴¹ The thymus is a small organ in your upper chest, under your breastbone. Before birth and during childhood, the thymus helps the body make a type of white blood cell. These cells help protect you from infections. Cancer of the thymus is rare. You are more likely to get it if you have other diseases such as myasthenia gravis, lupus or rheumatoid arthritis. Sometimes there are no symptoms. Other times, thymus cancer can cause: A cough that doesn't go away Chest pain Trouble breathing Doctors use a physical exam, imaging tests, and a biopsy to diagnose thymus cancer. The most common treatment is surgery to remove the tumor. Other options include radiation therapy, chemotherapy, and hormone therapy. NIH: National Cancer Institute

MalaCards based summary: Thymus Cancer, also known as malignant neoplasm of thymus, is related to good syndrome and thymic carcinoma. An important gene associated with Thymus Cancer is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are CD28 co-stimulation and Hematopoietic Stem Cells and Lineage-specific Markers. The drugs Pembrolizumab and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include thymus, lung and thyroid, and related phenotypes are neoplasm of the thymus and immunodeficiency

Disease Ontology: ¹¹ An immune system cancer located in the thymus.

Wikipedia: ⁷⁵ A thymoma is a tumor originating from the epithelial cells of the thymus that is considered a rare... more...

Sources

Related Diseases for Thymus Cancer

Diseases related to Thymus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 643)

#	Related Disease	Score	Top Affiliating Genes
1	good syndrome	32.3	CD8A CD4 CD274
2	thymic carcinoma	32.1	NKX2-1 KRT7 KIT CNTNAP2 CD5 CD274
3	thymoma	31.8	TTN NKX2-1 KRT7 KIT DPYSL5 CD8A
4	castleman disease	30.5	H2AC18 CD4 CCR6
5	thymus large cell carcinoma	30.5	KRT7 KIT CD5
6	cryptogenic organizing pneumonia	30.5	CD8A CD4 CD274
7	pure red-cell aplasia	30.4	CD8A CD4 AIRE
8	teratoma	30.4	NKX2-1 KRT7 KIT AKT1
9	lymphoepithelioma-like carcinoma	30.4	KRT7 KIT CD8A CD274
10	cortical thymoma	30.4	TTN AIRE
11	epithelial malignant thymoma	30.4	TTN CD5 AIRE
12	t-cell large granular lymphocyte leukemia	30.4	CD8A CD5 CD4
13	crescentic glomerulonephritis	30.4	ICOSLG CD8A CD4 CCR6
14	myasthenia gravis	30.4	TTN MUSK LRP4 AIRE
15	mediastinal cancer	30.3	NKX2-1 KRT7 KIT CD5
16	hemangioma	30.3	NKX2-1 KRT7 KIT AKT1
17	neuroendocrine carcinoma	30.3	NKX2-1 KRT7 KIT
18	lymphoma, mucosa-associated lymphoid type	30.3	ICOSLG CD5 CD4 CCR6
19	respiratory failure	30.3	TTN NKX2-1 MUSK H2AC18 CD8A CD4
20	pancreatic ductal adenocarcinoma	30.2	MIR205 MIR125A ICOSLG H2AC18 CCR6
21	myopathy	30.2	TTN ICOSLG H2AC18 CD8A CD4 CCR6
22	autoimmune disease	30.1	TTN MUSK ICOSLG CD5 CD274 CCR6
23	deficiency anemia	30.1	KIT ICOSLG H2AC18 CD8A CD5 CD4
24	thymus lymphoma	11.0
25	hilar lung neoplasm	10.5	CD8A CD4
26	proliferative glomerulonephritis	10.5	ICOSLG H2AC18 CCR6
27	lung carcinoma in situ	10.5	NKX2-1 KRT7 AKT1
28	lymphangitis	10.5	NKX2-1 KRT7 CD4
29	serous cystadenocarcinoma	10.5	KRT7 H2AC18 AKT1
30	ureter adenocarcinoma	10.5	NKX2-1 KRT7
31	gastroduodenitis	10.5	CD8A CD4 CCR6
32	laryngeal adenoid cystic carcinoma	10.5	KRT7 KIT
33	third ventricle chordoid glioma	10.5	NKX2-1 CD4
34	mucinous bronchioloalveolar adenocarcinoma	10.5	NKX2-1 KRT7
35	skin sarcoidosis	10.5	CD8A CD4 CCR6
36	syphilis	10.5	CD8A CD4 CCR6
37	ureter small cell carcinoma	10.5	NKX2-1 KRT7 KIT
38	invasive malignant thymoma	10.5	MUSK CD8A CD4
39	mikulicz disease	10.5	ICOSLG CD4 CCR6
40	autoimmune cholangitis	10.5	CD8A CD4 CCR6
41	farmer's lung	10.5	CD8A CD4 CCR6
42	oral tuberculosis	10.5	CD8A CD4
43	thymus clear cell carcinoma	10.5	NKX2-1 KIT CD5
44	follicular mucinosis	10.5	CD8A CD5 CD4
45	evans' syndrome	10.5	CD8A CD4 CCR6
46	basaloid squamous cell carcinoma	10.5	NKX2-1 KRT7 KIT
47	early yaws	10.5	CD8A CD4
48	parapsoriasis	10.5	CD8A CD5 CD4
49	thymus basaloid carcinoma	10.5	NKX2-1 CD5
50	primary cutaneous gamma-delta t-cell lymphoma	10.5	CD8A CD5 CD4

Graphical network of the top 20 diseases related to Thymus Cancer:

Sources

Symptoms & Phenotypes for Thymus Cancer

Human phenotypes related to Thymus Cancer:

⁵⁸ ³⁰ (show all 21)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	neoplasm of the thymus ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0100521
2	immunodeficiency ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002721
3	palpebral edema ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100540
4	dyspnea ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002094
5	cough ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012735
6	chest pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100749
7	mediastinal lymphadenopathy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0100721
8	diaphragmatic paralysis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0006597
9	dysgammaglobulinemia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002961
10	ptosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000508
11	dysphagia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002015
12	increased intracranial pressure ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002516
13	autoimmunity ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002960
14	pericarditis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001701
15	headache ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002315
16	abnormal bleeding ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001892
17	fatigable weakness ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003473
18	cardiac arrest ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001695
19	language impairment ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002463
20	neuroendocrine neoplasm ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100634
21	edema ⁵⁸		Frequent (79-30%)

MGI Mouse Phenotypes related to Thymus Cancer:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	9.73	AIRE AKT1 CCR6 CD4 CD8A CNTNAP2
2	no phenotypic analysis	MP:0003012	9.7	AIRE CD274 CD4 CD5 KIT MIR205
3	integument	MP:0010771	9.32	AKT1 CD274 CD4 CD5 CD8A KIT

Sources

Drugs & Therapeutics for Thymus Cancer

Drugs for Thymus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Pembrolizumab

Approved

Phase 4

1374853-91-4

254741536

Etoposide

Approved

Phase 3

33419-42-0

36462

Etoposide phosphate

Phase 3

16760419

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Pasireotide

Approved

Phase 2

396091-73-9

56841596 9941444

Octreotide

Approved, Investigational

Phase 2

83150-76-9

383414 6400441

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Somatostatin

Approved, Investigational

Phase 2

38916-34-6, 51110-01-1

53481605 16129706

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Busulfan

Approved, Investigational

Phase 2

55-98-1

2478

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

4159 6741

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Ramucirumab

Approved, Investigational

Phase 2

947687-13-0

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

9823820

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Nedaplatin

Approved, Investigational

Phase 2

95734-82-0

Cetuximab

Approved

Phase 2

205923-56-4

Nivolumab

Approved

Phase 1, Phase 2

946414-94-4

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Plicamycin

Approved, Investigational, Withdrawn

Phase 1, Phase 2

18378-89-7

163659 52945526

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Belinostat

Approved, Investigational

Phase 1, Phase 2

414864-00-9, 866323-14-0

53437714 6918638

Doxorubicin

Approved, Investigational

Phase 1, Phase 2

23214-92-8

31703

Doxepin

Approved, Investigational

Phase 2

1668-19-5

667468 667477

Histamine

Approved, Investigational

Phase 2

51-45-6

774

Diphenhydramine

Approved, Investigational

Phase 2

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 2

60-87-7

4927

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Amrubicin

Investigational

Phase 2

110267-81-7

13502539 3035016

Prednisolone hemisuccinate

Experimental

Phase 2

2920-86-7

4897

Lexatumumab

Investigational

Phase 2

845816-02-6

Vorolanib

Investigational

Phase 1, Phase 2

1013920-15-4

Molgramostim

Investigational

Phase 2

99283-10-0

Saracatinib

Investigational

Phase 2

379231-04-6

10302451

Interventional clinical trials:

(show top 50) (show all 98)

#	Name	Status	NCT ID	Phase	Drugs
1	Single-Arm Study to Carbo-paclitaxel/ Nab-paclitaxel Combined With Pembrolizumab as the First Line Therapy in Treating Patients With Locally Advanced or Metastatic Invasive Thymoma and Thymic Carcinoma That Cannot Be Removed by Surgery	Recruiting	NCT04554524	Phase 4	Chemotherapy+Pembrolizumab.
2	A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma	Unknown status	NCT02014805	Phase 3
3	An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection	Recruiting	NCT02633553	Phase 3
4	A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma	Recruiting	NCT02633514	Phase 3	Cisplatin;Etoposide
5	Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas	Unknown status	NCT02364076	Phase 2	Pembrolizumab;Epacadostat
6	Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort	Unknown status	NCT03921671	Phase 2
7	Samsung Medical Center	Unknown status	NCT03219554	Phase 2	Palbociclib
8	A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.	Unknown status	NCT03466827	Phase 2	Selinexor
9	A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies	Completed	NCT01364727	Phase 2	Amrubicin
10	An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND	Completed	NCT02307500	Phase 2	Regorafenib
11	A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy	Completed	NCT02607631	Phase 2	Pembrolizumab
12	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy	Completed	NCT02049047	Phase 2	Everolimus
13	Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size	Completed	NCT02021942	Phase 2	SOM230 LAR
14	Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence	Completed	NCT00387868	Phase 2	cisplatin and etoposide
15	A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma	Completed	NCT00369889	Phase 2	bevacizumab;Erlotinib
16	A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin	Completed	NCT02420691	Phase 2	Ribociclib
17	A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma	Completed	NCT00589290	Phase 2	Belinostat (PDX101)
18	Radiofrequency Ablation of Pulmonary Malignancy	Completed	NCT00024076	Phase 2
19	Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma	Completed	NCT00010257	Phase 2	carboplatin;paclitaxel
20	Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study	Completed	NCT00990535	Phase 2	Octreotide-LAR
21	Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size	Completed	NCT00332969	Phase 2	Octreotide
22	Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma	Completed	NCT00198133	Phase 2	Premetrexed (Alimta)
23	Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma	Completed	NCT00003283	Phase 2	octreotide acetate;prednisone
24	Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy	Completed	NCT00965250	Phase 2	IMC-12
25	A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors	Completed	NCT01312324	Phase 2	neoadjuvant docetaxel/cisplatin
26	Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies	Completed	NCT01163552	Phase 2
27	A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas	Completed	NCT02220855	Phase 2	BKM120
28	A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma	Completed	NCT02623127	Phase 2	Sunitinib
29	A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases	Completed	NCT00003662	Phase 2	busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
30	A Phase II, Neo-adjuvant Pembrolizumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Pembrolizumab Consolidation Therapy in Locally Advanced Thymic Epithelial Tumor (TET)	Recruiting	NCT03858582	Phase 2	pembrolizumab
31	A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy	Recruiting	NCT03076554	Phase 2	Avelumab
32	Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy	Recruiting	NCT03134118	Phase 2	Nivolumab
33	A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma	Recruiting	NCT04417660	Phase 2	M7824
34	A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma	Recruiting	NCT05104736	Phase 2	PT-112
35	Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)	Recruiting	NCT03449173	Phase 2	Sunitinib
36	A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma	Recruiting	NCT03694002	Phase 2	Carboplatin;Paclitaxel
37	An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma	Recruiting	NCT04321330	Phase 2	Atezolizumab
38	A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI.	Recruiting	NCT04710628	Phase 2	Pembrolizumab;Lenvatinib 10 mg
39	A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma	Recruiting	NCT04469725	Phase 2	KN046
40	Phase II Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors	Recruiting	NCT04925947	Phase 2	KN046
41	A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma	Recruiting	NCT03463460	Phase 2	Sunitinib Malate
42	A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy	Active, not recruiting	NCT01621568	Phase 2	Sunitinib
43	Hypofractionated Radiotherapy Combined With Concurrent Weekly Chemotherapy and Thymosin α1 in Patients With Unresectable or Recurrent Thymic Epithelial Tumor: A Prospective, Single-arm Phase II Study	Active, not recruiting	NCT03663764	Phase 2	Thymosin a1;concurrent chemoradiotherapy
44	A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007)	Active, not recruiting	NCT01025089	Phase 2	Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
45	Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors	Active, not recruiting	NCT03583086	Phase 1, Phase 2	VEGFR/PDGFR Dual Kinase Inhibitor X-82
46	Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor	Not yet recruiting	NCT04667793	Phase 2	Toripalimab;Chemotherapy
47	Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors	Not yet recruiting	NCT04517539	Phase 2	rhGM-CSF，Peginterferon alfa-b2，radiation
48	Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases	Terminated	NCT02859415	Phase 1, Phase 2	Mithramycin
49	Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma)	Terminated	NCT00718809	Phase 2	saracatinib
50	A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma	Terminated	NCT00818090	Phase 2	paclitaxel and cisplatin

Search NIH Clinical Center for Thymus Cancer

Cochrane evidence based reviews: thymus neoplasms

Sources

Genetic Tests for Thymus Cancer

Sources

Anatomical Context for Thymus Cancer

Organs/tissues related to Thymus Cancer:

FMA: Thymus

MalaCards : Thymus, Lung, Thyroid, T Cells, B Cells, Bone Marrow, Liver

Sources

Publications for Thymus Cancer

Articles related to Thymus Cancer:

(show top 50) (show all 493)

#	Title	Authors	PMID	Year
1	CD59 Expression in Skeletal Muscles and Its Role in Myasthenia Gravis. ⁴¹	Iwasa K...Ono K	36396448	2023
2	Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. ⁴¹	Gao W...Guo R	36450378	2022
3	Prognostic value of tumor size in thymic epithelial tumors: A systematic review and meta-analysis. ⁴¹	Shao Y...Liu W	36401408	2022
4	Utility of immunohistochemistry in separating thymic neoplasms from germ cell tumors and metastatic lung cancer involving the anterior mediastinum. ⁵³ ⁶²	Saad RS...Silverman JF	12777991	2003
5	Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms. ⁵³ ⁶²	Pomplun S...Nicholson AG	11952859	2002
6	Incidental Detection of a Type B3 Thymoma on 68Ga-FAPI-04 PET/CT Imaging. ⁶²	Kepenek F...Can C	36469078	2023
7	Thymic lipofibroadenoma of the anterior mediastinum: A rare case report. ⁶²	Fu J...Li XL	36401401	2022
8	Approach to Mediastinal Fine Needle Aspiration Cytology. ⁶²	Li Z...Fan F	35838636	2022
9	LCK-Mediated RIPK3 Activation Controls Double-Positive Thymocyte Proliferation and Restrains Thymic Lymphoma by Regulating the PP2A-ERK Axis. ⁶²	Hwang SM...Kim YS	36161785	2022
10	Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. ⁶²	Liu S...Song W	36401466	2022
11	Rare case of an exceedingly enlarged mediastinal mass in 22-year-old male. ⁶²	Hooda Z...Connolly M	36324768	2022
12	Added Value of Magnetic Resonance Over Computed Tomography in Distinguishing Nonneoplastic Complex Thymic Cysts From Malignant Cystic Thymic Neoplasms. ⁶²	Madan R...Hammer MM	36103678	2022
13	Modified subcostal arch xiphoid thoracoscopic expanded thymectomy for thymic carcinoma: a case report and review of literature. ⁶²	Wang J...Zhao Y	36088333	2022
14	Early development of pembrolizumab-induced fulminant myositis and cardiotoxicity in a patient with metastatic thymoma. ⁶²	Jang SY...Choi J	36034177	2022
15	Early Detection of Relapse by ctDNA Sequencing in a Patient with Metastatic Thymic Tumor and MEN1 Mosaicism. ⁶²	Lagarde A...Romanet P	35904487	2022
16	Lifetime Exposure to Welding Fumes and Risk of Some Rare Cancers. ⁶²	Kendzia B...Behrens T	35872594	2022
17	Thymoma (World Health Organization Type AB) in multiple endocrine neoplasia type 1: a case report. ⁶²	Fan Z...Gu C	35821790	2022
18	Pretracheal ectopic thymoma: A diagnostic challenge in endobronchial ultrasound-guided transbronchial needle aspiration cytology. ⁶²	George E...Dorey N	35445470	2022
19	Management of incidentally detected small anterior mediastinal nodules: Which way to go? ⁶²	Fang W...Zhu L	35462112	2022
20	Ectopic adrenocorticotrophic hormone syndrome initially presenting as abnormal mental behavior caused by thymic carcinoid: a case report. ⁶²	Han X...Chen C	35531113	2022
21	COMPARATIVE ANALYSIS OF CURRENT SURGICAL APPROACHES TO THYMIC TUMORS TREATMENT. ⁶²	Lagvilava A...Chaduneli G	35417859	2022
22	[Mediastinal lesions : The most common pathologies in chest X-rays and their correlations in computed tomography]. ⁶²	Loffler MT...Ehritt-Braun C	35024887	2022
23	Differentiating thymoma, thymic carcinoma and lymphoma based on collagen fibre patterns with T2- and diffusion-weighted magnetic resonance imaging. ⁶²	Hu YC...Cui GB	34215941	2022
24	Factors predicting perioperative outcomes in patients with myasthenia gravis or thymic neoplasms undergoing thymectomy by video-assisted thoracoscopic approach. ⁶²	Vigneshwaran B...Kar M	35017401	2022
25	Surgical management of locally advanced thymic neoplasms. ⁶²	Akcelik A...Abbas AE	35340838	2022
26	Current Roles of PET/CT in Thymic Epithelial Tumours: Which Evidences and Which Prospects? A Pictorial Review. ⁶²	Lococo F...Margaritora S	34885200	2021
27	Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. ⁶²	Vlasenkova R...Kiyamova R	34944522	2021
28	Regression of thymoma-induced lichenoid hypersensitivity reactions of the oral mucosa following thymoma treatment: a case report. ⁶²	Fantozzi PJ...Romeo U	34678738	2021
29	Viral infection in thymoma and thymic tumors with autoimmune diseases. ⁶²	Chang R...Zhang P	34532982	2021
30	A Rare Thymic Tumor - Lipofibroadenoma - Always a Postoperative Surprise. ⁶²	Bolca C...Cordos I	34697204	2021
31	Thymic tumours: a single center surgical experience and literature review on the current diagnosis and management of thymic malignancies. ⁶²	Minervini F...Kocher GJ	34926228	2021
32	Surgical management of locally invasive basaloid carcinoma of thymic gland. ⁶²	Lee ACH...Podbielski FJ	34858582	2021
33	Lymph Nodes Involvement and Lymphadenectomy in Thymic Tumors: Tentative Answers for Unsolved Questions. ⁶²	Brascia D...Marulli G	34680234	2021
34	Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus. ⁶²	Mandl A...Agarwal SK	34515662	2021
35	Thymolipoma and its Association with Myasthenia Gravis: a Multi-center Experience. ⁶²	Hamouri S...Barakat F	35169361	2021
36	Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. ⁶²	Zhai Y...Feng Q	33174515	2021
37	Diffuse panbronchiolitis as parathymic syndrome in a Caucasian man previously treated for thymoma. ⁶²	Carnevale A...Marku B	34408804	2021
38	Thymic Carcinoma With Multiple Paraneoplastic Disorders. ⁶²	Alexakou Z...Alexopoulou A	33961845	2021
39	Tumor immunity is related to 18 F-FDG uptake in thymic epithelial tumor. ⁶²	Imai H...Kagamu H	34363337	2021
40	Recurrent anti-AMPA receptor encephalitis associated with thymus cancer. ⁶²	Qiao S...Liu XW	33939040	2021
41	Micronodular Thymoma with Lymphoid Stroma: A Case Report. ⁶²	Tsuchiya T...Kawashima M	34216482	2021
42	Development of thymic tumor in [LSL:KrasG12D; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis. ⁶²	Liot S...Lambert E	34302028	2021
43	Urgent lung transplantation for thymic neoplasm-associated severe constrictive bronchiolitis with bronchiectasis and radiotherapy-induced organizing pneumonia: A case report. ⁶²	Stupnik T...Skrgat S	33830653	2021
44	Dual-scopic robotic thymectomy for a large thymic malignant tumor. ⁶²	Yanagiya M...Matsumoto J	34221347	2021
45	De novo hepatocellular carcinoma in a non-cirrhotic allograft 27 years after liver transplantation: A case report. ⁶²	El-Domiaty N...Samuel D	33382179	2021
46	Thymic Metastasis of Ovarian Cancer 33 Years After Primary Surgery. ⁶²	Omura A...Shintani Y	33130116	2021
47	Apoptosis inducing properties of 3-biotinylate-6-benzimidazole B-nor-cholesterol analogues. ⁶²	Zhu Z...Gan C	33722574	2021
48	[Chinese guideline for clinical diagnosis and treatment of thymic epithelial tumors (2021 Edition)]. ⁶²	Multidisciplinary Committee of Oncology, Chinese Physicians Association	33902202	2021
49	Prosthetic Reconstruction of Superior Vena Cava System for Thymic Tumor: A Retrospective Analysis of 22 Cases. ⁶²	Zhang Z...Pan X	32005044	2021
50	Comparison of Subxiphoid and Intercostal Uniportal Thoracoscopic Thymectomy for Nonmyasthenic Early-Stage Thymoma: A Retrospective Single-Center Propensity-Score Matching Analysis. ⁶²	Liu Z...Yang R	32886931	2021

Sources

Genes for Thymus Cancer

Genes related to Thymus Cancer (0 elite genes):

(show all 50)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NKX2-1	NK2 Homeobox 1	Protein Coding	12.49	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12777991 11952859
2	KRT7	Keratin 7	Protein Coding	11.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11952859 12777991
3	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	8.45	DISEASES inferred ¹⁴ ¹⁴
4	MUSK	Muscle Associated Receptor Tyrosine Kinase	Protein Coding	8.29	DISEASES inferred ¹⁴
5	MIR205	MicroRNA 205	RNA Gene	7.58	DISEASES inferred ¹⁴ ¹⁴
6	H2AC18	H2A Clustered Histone 18	Protein Coding	7.53	DISEASES inferred ¹⁴ ¹⁴
7	CD8A	CD8a Molecule	Protein Coding	7.48	DISEASES inferred ¹⁴
8	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	7.38	DISEASES inferred ¹⁴
9	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	7.33	DISEASES inferred ¹⁴ ¹⁴
10	CD4	CD4 Molecule	Protein Coding	7.33	DISEASES inferred ¹⁴
11	CD5	CD5 Molecule	Protein Coding	7.3	DISEASES inferred ¹⁴
12	TTN	Titin	Protein Coding	7.24	DISEASES inferred ¹⁴
13	DPYSL5	Dihydropyrimidinase Like 5	Protein Coding	7.16	DISEASES inferred ¹⁴
14	LGI1	Leucine Rich Glioma Inactivated 1	Protein Coding	7.13	DISEASES inferred ¹⁴
15	AIRE	Autoimmune Regulator	Protein Coding	7.05	DISEASES inferred ¹⁴
16	CNTNAP2	Contactin Associated Protein 2	Protein Coding	7.03	DISEASES inferred ¹⁴
17	MIR125A	MicroRNA 125a	RNA Gene	7.03	DISEASES inferred ¹⁴ ¹⁴
18	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	6.94	DISEASES inferred ¹⁴
19	LRP4	LDL Receptor Related Protein 4	Protein Coding	6.7	DISEASES inferred ¹⁴
20	CD274	CD274 Molecule	Protein Coding	6.66	DISEASES inferred ¹⁴
21	TP53	Tumor Protein P53	Protein Coding	6.66	DISEASES inferred ¹⁴
22	MIR140	MicroRNA 140	RNA Gene	6.61	DISEASES inferred ¹⁴ ¹⁴
23	IL2	Interleukin 2	Protein Coding	6.58	DISEASES inferred ¹⁴
24	KCNA4	Potassium Voltage-Gated Channel Subfamily A Member 4	Protein Coding	6.55	DISEASES inferred ¹⁴
25	AMPH	Amphiphysin	Protein Coding	6.55	DISEASES inferred ¹⁴
26	GTF2I	General Transcription Factor IIi	Protein Coding	6.52	DISEASES inferred ¹⁴
27	PNMA2	PNMA Family Member 2	Protein Coding	6.51	DISEASES inferred ¹⁴
28	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	6.49	DISEASES inferred ¹⁴
29	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	6.48	DISEASES inferred ¹⁴
30	MIR126	MicroRNA 126	RNA Gene	6.44	DISEASES inferred ¹⁴ ¹⁴
31	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.33	DISEASES inferred ¹⁴
32	DNTT	DNA Nucleotidylexotransferase	Protein Coding	6.33	DISEASES inferred ¹⁴
33	AGRN	Agrin	Protein Coding	6.31	DISEASES inferred ¹⁴
34	PTPRC	Protein Tyrosine Phosphatase Receptor Type C	Protein Coding	6.27	DISEASES inferred ¹⁴
35	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.25	DISEASES inferred ¹⁴
36	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.05	DISEASES inferred ¹⁴
37	KRT5	Keratin 5	Protein Coding	6.03	DISEASES inferred ¹⁴
38	BCL2	BCL2 Apoptosis Regulator	Protein Coding	6.01	DISEASES inferred ¹⁴
39	LCK	LCK Proto-Oncogene, Src Family Tyrosine Kinase	Protein Coding	6	DISEASES inferred ¹⁴
40	FOXP3	Forkhead Box P3	Protein Coding	6	DISEASES inferred ¹⁴
41	CD1C	CD1c Molecule	Protein Coding	5.99	DISEASES inferred ¹⁴
42	CD1E	CD1e Molecule	Protein Coding	5.99	DISEASES inferred ¹⁴
43	CD1D	CD1d Molecule	Protein Coding	5.98	DISEASES inferred ¹⁴
44	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	5.98	DISEASES inferred ¹⁴
45	PDCD1	Programmed Cell Death 1	Protein Coding	5.97	DISEASES inferred ¹⁴
46	CD1A	CD1a Molecule	Protein Coding	5.96	DISEASES inferred ¹⁴
47	CD1B	CD1b Molecule	Protein Coding	5.96	DISEASES inferred ¹⁴
48	MIR142	MicroRNA 142	RNA Gene	5.94	DISEASES inferred ¹⁴ ¹⁴
49	PSMB11	Proteasome Subunit Beta 11	Protein Coding	5.93	DISEASES inferred ¹⁴
50	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	5.92	DISEASES inferred ¹⁴

Sources

Variations for Thymus Cancer

Cosmic variations for Thymus Cancer:

⁸ (show all 36)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM105695698	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.376T>A	p.Y126N	17:7675236-7675236	13
2	COSM142891951	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.376T>A	p.Y126N	17:7675236-7675236	13
3	COSM87975416	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.376T>A	p.Y126N	17:7675236-7675236	13
4	COSM142627127	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.259T>A	p.Y87N	17:7675236-7675236	13
5	COSM121944830	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.-21T>A	p.?	17:7675236-7675236	13
6	COSM106116533	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.376T>A	p.Y126N	17:7675236-7675236	13
7	COSM144072853	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.343T>A	p.Y115N	17:7675236-7675236	13
8	COSM144363948	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.259T>A	p.Y87N	17:7675236-7675236	13
9	COSM122332176	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.-21T>A	p.?	17:7675236-7675236	13
10	COSM93250189	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.376T>A	p.Y126N	17:7675236-7675236	13
11	COSM145076506	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.259T>A	p.Y87N	17:7675236-7675236	13
12	COSM122804157	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.-21T>A	p.?	17:7675236-7675236	13
13	COSM144718880	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.259T>A	p.Y87N	17:7675236-7675236	13
14	COSM144140974	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.-102T>A	p.?	17:7675236-7675236	13
15	COSM112319052	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.376T>A	p.Y126N	17:7675236-7675236	13
16	COSM143214478	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.-102T>A	p.?	17:7675236-7675236	13
17	COSM143433019	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.259T>A	p.Y87N	17:7675236-7675236	13
18	COSM111826108	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.376T>A	p.Y126N	17:7675236-7675236	13
19	COSM144005441	TP53	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.-102T>A	p.?	17:7675236-7675236	13
20	COSM103083119	SMAD4	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.1081C>T	p.R361C	18:51065548-51065548	13
21	COSM139771670	SMAD4	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.793C>T	p.R265C	18:51065548-51065548	13
22	COSM91380576	SMAD4	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.1081C>T	p.R361C	18:51065548-51065548	13
23	COSM88596522	PREX2	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.107G>T	p.R36L	8:67952501-67952501	13
24	COSM88408638	NOTCH2	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.3359G>A	p.C1120Y	1:119937445-119937445	13
25	COSM87667907	KMT2D	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.12634C>T	p.R4212W	12:49032071-49032071	13
26	COSM88314740	KIT	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.1657T>A	p.Y553N	4:54727425-54727425	13
27	COSM132270273	KDM6A	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.2768C>T	p.A923V	23:45078488-45078488	13
28	COSM101719617	KDM6A	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.2870C>T	p.A957V	23:45078488-45078488	13
29	COSM145420036	KDM6A	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.*1915C>T	p.?	23:45078488-45078488	13
30	COSM143359668	KDM6A	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.3005C>T	p.A1002V	23:45078488-45078488	13
31	COSM102181889	KDM6A	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.2921C>T	p.A974V	23:45078488-45078488	13
32	COSM132025397	KDM6A	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.2714C>T	p.A905V	23:45078488-45078488	13
33	COSM85170206	IL7R	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.537+1G>T	p.?	5:35871214-35871214	13
34	COSM121730466	IL7R	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.537+1G>T	p.?	5:35871214-35871214	13
35	COSM143857324	FAT1	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.12712A>G	p.K4238E	4:186596834-186596834	13
36	COSM110448949	FAT1	thymus,NS,thymic carcinoma,undifferentiated carcinoma	c.12706A>G	p.K4236E	4:186596834-186596834	13

Sources

Expression for Thymus Cancer

Search GEO for disease gene expression data for Thymus Cancer.

Sources

Pathways for Thymus Cancer

Pathways related to Thymus Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	CD28 co-stimulation ⁶⁶ Show member pathways Activation of AKT2 ⁶⁶ CD28 dependent PI3K/Akt signaling ⁶⁶ CD28 dependent Vav1 pathway ⁶⁶ Costimulation by the CD28 family ⁶⁶ CTLA4 Signaling ⁶⁴ VEGFR2 mediated vascular permeability ⁶⁶	11.73	ICOSLG CD8A CD4 CD274 AKT1
2	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.52	KIT CD8A CD5 CD4
3	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.38	CD8A CD4 AKT1
4	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.3	KIT CD8A CD4
5	Innate Lymphoid Cells Differentiation ⁶⁵	10.83	KIT CD8A CD4 CCR6

Sources

GO Terms for Thymus Cancer

Cellular components related to Thymus Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.47	KIT ICOSLG CD8A CD5 CD4 CD274

Biological processes related to Thymus Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	9.76	MUSK KIT CD8A CD4
2	T cell costimulation	GO:0031295	9.43	CD5 CD274 AKT1
3	positive regulation of gene expression	GO:0010628	9.36	TTN NKX2-1 MUSK MIR205 MIR125A KIT